

Academic Partners

Stichting Katholieke Universiteit, Radboud University Medical Center Netherlands
King's College London United Kingdom
Medizinische Universität Graz Austria
University of Cambridge United Kingdom
Centre Hospitalier Universitaire Montpellier France
University of Southern Denmark Denmark
University of Lausanne Switzerland
University of Sheffield United Kingdom
Nordsjællands University Hospital Hillerød Denmark
University of Dundee, School of Medicine United Kingdom
EURICE – European Research and Project Office GmbH Germany
SIB Swiss Institute of Bioinformatics Switzerland
Università Degli Studi di Padova Italy
University of Edinburgh United Kingdom

Industry Partners

Novo Nordisk A/S Denmark
Eli Lilly and Company Limited United Kingdom
Sanofi-Aventis Deutschland GmbH Germany
Abbott, Diabetes Care United States of America
Medtronic Switzerland

Associated Partners

JDRF United States of America
International Diabetes Federation IDF Belgium
T1D Exchange United States of America
The Leona M. and Harry B. Helmsley Charitable Trust United States of America



Coordination

Dr Bastiaan de Galan
Radboud University Medical
Center

www.Hypo-RESOLVE.eu


Follow us on twitter @HypoResolve

Project Lead

Dr Stephen Gough
Novo Nordisk A/S

Management

EURICE - European Research
and Project Office GmbH



HYPO RESOLVE

Hypo-RESOLVE Investigates
Hypoglycaemia and its Impact in Diabetes



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777460. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, International Diabetes Federation (IDF), and the Leona M. and Harry B. Helmsley Charitable Trust.

Hypo-RESOLVE

Hypoglycaemia – REdefining SOLutions for better LIVEs

Why do we need research on Hypoglycaemia?

Diabetes is a global pandemic, currently affecting around 60 million people in Europe. Hypoglycaemia is a common and serious complication of diabetes, particularly affecting people on insulin therapy. Consisting of very low levels of blood glucose, hypoglycaemia may lead to cognitive decline, cardiovascular events and even death. Despite these potentially dramatic consequences for people living with diabetes, very little is known about hypoglycaemia – a fact resulting in a lack of prevention and treatment.

Why do we need Hypo-RESOLVE?

The overall aim of the international research project Hypo-RESOLVE is to reduce the burden and consequences of hypoglycaemia for people living with diabetes. This requires finding answers to questions which, nearly 100 years after the discovery of insulin, still need to be solved.

Hypo-RESOLVE aims to provide evidence-based classification of hypoglycaemia to achieve better treatments for people living with diabetes.



Duration
48 months



Budget
€ 26.8 Mio



23 partners
10 countries



Dr Bastiaan de Galan
Radboud University Medical Center (Project Coordinator)

“We will use the power of statistics to make valid statements about the glucose thresholds below which hypoglycaemia constitutes a great risk for people living with diabetes aiming to improve the quality of their everyday lives.”



Dr Stephen Gough
Novo Nordisk A/S (Project Lead)

“This consortium brings together world leaders from the field of diabetes to reduce the burden of hypoglycaemia. Hypo-RESOLVE paves the way for further research on glucose-lowering interventions that will serve people living with diabetes, clinicians and healthcare companies.”

Hypo-RESOLVE aims to provide more validated data to researchers and clinicians about the condition of hypoglycaemia by:

- Creating a sustainable clinical database;
- Performing studies to better understand the underlying mechanisms of hypoglycaemia;
- Conducting a series of statistical analyses to define predictors and consequences of hypoglycaemia;
- Calculating the financial cost in European countries.

Watch our video
hypo-resolve.eu/project



Hypo-RESOLVE – An Integrated multi-level approach

The Hypo-RESOLVE consortium includes the full expertise needed to lift the understanding of hypoglycaemia to the next level. It has assembled a unique international consortium of leading experts in basic, clinical, psychological/behavioural and economic aspects of hypoglycaemia research, who will work collaboratively with industry partners and other stakeholder groups.

It is their collective aim to tackle the challenges of hypoglycaemia through a comprehensive multi-level approach putting the voices and needs of people living with diabetes at the heart of their research.

Expert groups like the Patient Advisory Committee, the Strategic Advisory Board and the Ethics Board will complement the expertise of the consortium and provide independent advice and recommendations.